期刊文献+

治疗糖尿病肾病新药研究进展

原文传递
导出
摘要 糖尿病肾脏疾病(Diabetic kidney disease,DKD)是糖尿病的严重微血管并发症之一.近年来,基于DKD发病率高、治疗困难、预后差的特点及经典综合治疗方案(包括控制血压、血糖,应用RAS阻滞剂)疗效的有限性,临床迫切需要更有效的新型药物.因此,研究者们也在积极地开发和探索,并取得了一定的成果,发现了一系列治疗DKD的“新药”.因此,本文将主要针对其发病机制的治疗靶点对近年来出现的治疗DKD的新型药物进行综述.
出处 《国际泌尿系统杂志》 2017年第2期290-295,共6页 International Journal of Urology and Nephrology
基金 国家自然科学基金面上项目(81273575)
  • 相关文献

参考文献1

二级参考文献34

  • 1Basra, G., 2008. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis, 196(1):9-21. [doi:10.1016/ j. atherosclorosis.2007.07.025].
  • 2Bohlender, J.M., Franke, S., Stein, G., Wolf, G., 2005. Ad- vanced glycation end products and the kidney. Am. J. Physiol. Renal. PhysioL, 289(4):F645-F659. [doi:10. 1152/ajpronal.00398.2004].
  • 3Cohen, M.P., Ziyadeh, F.N., 1996. Role of Amadori-modified nonenzymatically glycated serum proteins in the patho- genesis of diabetic nephropathy.J. Am. Soc. Nephrol., 7(2):183-190.
  • 4Cohen, M.P., Ziyadeh, F.N., Chen, S., 2006. Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes: pathogenic and therapeutic implications. J. Lab. Clin. Med., 147(5):211-219. [doi:10.1016/j.lab.2005. 12.006].
  • 5Cuccurullo, C., Iezzi, A., Fazia, M.L., de Cesare, D., di Fran- cesco, A., Muraro, R., Bei, R., Ucchino, S., Spigonardo, F., Chiarelli, F., et al., 2006. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler. Thromb. Vasc. BioL, 26(12) 2716-2723. [doi:10.1161/01.ATV.0000249630.02085.12].
  • 6Devangelio, E., Santilli, F., Formoso, G., Ferroni, P., Bucci- arelli, L., Michetti, N., Clissa, C., Ciabattoni, G., Consoli, A., Davi, G., 2007. Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic. BioL Med., 43(4):511-518. [doi:10.1016/j.freoradbiomod.2007.03.015].
  • 7Flyvbjerg, A., Denner, L., Schrijvers, B.F., Tilton, R.G., Mo- gensen, T.H., Paludan, S.R., Rasch, R., 2004. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes, 53(1):166-172. [doi:10. 23371diabotos.53.1.166].
  • 8Forbes, J.M., Thorpe, S.R., Thallas-Bonke, V., Pete, J., Tho- mas, M.C., Deemer, E.R., Bassal, S., E1-Osta, A., Long, D.M., Panagiotopoulos, S., et al., 2005. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J. Am. Soc. Nephrol., 16(8):2363-2372. [doi:10.1681/ASN.2005010062].
  • 9Fried, L.F., Orchard, T.J., Kasiske, B.L., 2001. Effect of lipid reduction on the progression of renal disease: a meta- analysis. Kidney Int., 59(1):260-269. [doi:10.1046/].1523- 1755.2001.00487.x].
  • 10Gohda, T., Tanimoto, M., Moon, J.Y., Gotoh, H., Aoki, T., Matsumoto, M., Shibata, T., Obsawa, I., Funabiki, K., Tomino, Y., 2008. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function. Diabetes Res. Clin. Pract., 81(2):196-201. [doi:10.1016/j.diabres.2008.04.013].

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部